GSK (LON:GSK) Posts Quarterly Earnings Results

GSK (LON:GSK) posted its quarterly earnings results on Wednesday. The company reported GBX 23.20 ($0.29) EPS for the quarter, Digital Look Earnings reports. GSK had a net margin of 12.83% and a return on equity of 33.30%.

GSK Stock Performance

Shares of LON GSK traded down GBX 36 ($0.45) during trading hours on Friday, reaching GBX 1,443.50 ($17.95). 59,094,820 shares of the stock were exchanged, compared to its average volume of 31,571,498. The stock’s fifty day simple moving average is GBX 1,356.75 and its 200 day simple moving average is GBX 1,457.45. The firm has a market capitalization of £58.89 billion, a price-to-earnings ratio of 1,277.43, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a 52 week low of GBX 1,282.50 ($15.95) and a 52 week high of GBX 1,823.50 ($22.68). The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GSK shares. Berenberg Bank lowered their target price on shares of GSK from GBX 1,820 ($22.63) to GBX 1,600 ($19.90) and set a “buy” rating on the stock in a research note on Friday, November 29th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.46).

Insider Transactions at GSK

In related news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.35) per share, for a total transaction of £19,725 ($24,530.53). Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.